Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Bristol holds option to acquire F-star Alpha and its FS102; withdrawn

Executive Summary

Bristol-Myers Squibb Co. received the exclusive option to acquire F-star Alpha Ltd. BMS may exercise the option when and if it decides to proceed with a Phase IIb trial for F-star Alpha's preclinical antibody FS102 for HER2-positive breast and gastric cancer.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Withdrawn
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash
    • Acquisition of Private Biotech
    • Includes Earnout

Related Companies

UsernamePublicRestriction

Register